# Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs

> **NCT00343915** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 267 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Engerix™-B (thiomersal-free) 20µg
- **BIOLOGICAL:** 10 μg Engerix™-B (preservative-free)
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT00343915
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04-21
- **Primary completion:** 2008-01-10
- **Final completion:** 2008-01-10
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2019-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343915, "Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00343915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*